Ibudilast awarded patent for treating progressive MS, Europe
Posted: Fri Oct 26, 2012 2:12 am
Biopharmaceutical company MediciNova Inc reported on Thursday the receipt of a Notice of Allowance from the European Patent Office for an application covering the use of ibudilast for progressive forms of multiple sclerosis (MS), a chronic disease in which disability progresses over time.
According to the company, ibudilast (MN-166) is its drug development candidate for certain neurological conditions, including primary progressive or secondary progressive MS, drug addiction and pain.
The company's patent maturing from this allowed patent application is expected to expire no earlier than early 2029 and covers a method of treating progressive MS.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1311